Efficacy and Safety of Chinese Herbal Medicine (T50) added to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus: A 12-week randomised, double-blind, placebo-controlled pilot clinical trial

Zhao, Yi

Efficacy and Safety of Chinese Herbal Medicine (T50) added to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus: A 12-week randomised, double-blind, placebo-controlled pilot clinical trial

Zhao, Yi

Permalink

Publication Type:: Thesis
Issue Date:: 2024

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download thesisAdobe PDF (1.55 MB)

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Zhao, Yi
dc.date.accessioned	2026-02-10T01:06:06Z
dc.date.available	2026-02-10T01:06:06Z
dc.date.issued	2024
dc.identifier.uri	http://hdl.handle.net/10453/193133
dc.description	University of Technology Sydney. Faculty of Science.	en_US.UTF-8
dc.description.abstract	This clinical trial evaluated the efficacy and safety of T50, a traditional Chinese herbal formula, as an add-on treatment to metformin in individuals with type 2 diabetes mellitus (T2DM) who had insufficient blood glucose control. Forty-two participants with HbA1c levels between 7 to 9% and using metformin monotherapy were enrolled. They were randomized to receive either T50 or placebo over a 12-week period. The study’s primary goal was to assess changes in HbA1c level. Results showed a reduction in HbA1c in the T50 group compared to placebo. Additionally, T50 improved insulin resistance as indicated by a decrease in HOMA-IR scores, without affecting pancreatic β-cell function. No significant changes were observed in other metabolic indicators such as BMI or lipid levels. Liver and kidney functions remained stable. The treatment was well tolerated, with no serious side effects reported. These findings suggest that T50 may be a beneficial complementary therapy for improving glycaemic control in T2DM patients on metformin, although further large-scale and long-term studies are recommended.	en_US.UTF-8
dc.format	Thesis (MSc)
dc.language.iso	en_US	en_US.UTF-8
dc.rights	info:eu-repo/semantics/openAccess
dc.rights	The author owns the copyright in this thesis including all reproduction and reuse rights for the work. The work may not be altered without the permission of the copyright owner. Attribution is essential when quoting or paraphrasing from this thesis.
dc.rights	© 2024 Yi Zhao
dc.rights	au.edu.uts.lib/nph
dc.title	Efficacy and Safety of Chinese Herbal Medicine (T50) added to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus: A 12-week randomised, double-blind, placebo-controlled pilot clinical trial	en_US.UTF-8
dc.type	Thesis
utslib.copyright.status	open_access	*

Abstract:

This clinical trial evaluated the efficacy and safety of T50, a traditional Chinese herbal formula, as an add-on treatment to metformin in individuals with type 2 diabetes mellitus (T2DM) who had insufficient blood glucose control. Forty-two participants with HbA1c levels between 7 to 9% and using metformin monotherapy were enrolled. They were randomized to receive either T50 or placebo over a 12-week period. The study’s primary goal was to assess changes in HbA1c level. Results showed a reduction in HbA1c in the T50 group compared to placebo. Additionally, T50 improved insulin resistance as indicated by a decrease in HOMA-IR scores, without affecting pancreatic β-cell function. No significant changes were observed in other metabolic indicators such as BMI or lipid levels. Liver and kidney functions remained stable. The treatment was well tolerated, with no serious side effects reported. These findings suggest that T50 may be a beneficial complementary therapy for improving glycaemic control in T2DM patients on metformin, although further large-scale and long-term studies are recommended.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/193133